



**Alliance for Clinical Trials in Oncology**  
**Friday, November 2, 2018**  
**Loews Hotel Chicago O'Hare**  
**12:30 pm – 3:30 pm**  
**Teleconf #: 1-800-501-8979**  
**Access code: 3057352 / Chair code: 3307**

## **Neurooncology Committee Meeting Agenda**

Chair: Evanthia Galanis, MD

### **Welcome – Overview**

E. Galanis

### **Newly Diagnosed GBM**

#### Active Protocols

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation J. Sarkaria

#### Recently Completed Trials

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA] Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma (Published, Neurooncology) E. Galanis

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (Manuscript in preparation) N. Laack

### **Recurrent GBM**

#### Concepts in Development

A071702: A Phase II Study of Anti-PD-1/PD-L1 Blockade Immunotherapy in Patients with Hypermutated Recurrent Glioblastoma G. Dunn  
E. Galanis  
D. Reardon

#### Active Protocols

EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma T. Kaufmann

#### Recently Completed Trials

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Manuscript submitted) E. Galanis

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma (GBM) – (Manuscript in preparation) O. Bloch  
I. Parney

N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma (Manuscript in preparation) E. Galanis

### **CNS Lymphoma**

Randomized Phase II Trial of Lenalidomide Maintenance vs. High-Dose Cytarabine Consolidation after Methotrexate, Temozolomide, Rituximab (MT-R) Induction in Older Patients with newly diagnosed primary CNS lymphoma A. Alencar  
J. Rubenstein

### **Brain Metastases**

#### Active Trials

CCTG/Alliance CE.7: A Phase III Trial of Radiosurgery (SRS) vs. WBRT for Multiple (5-15) Brain Metastases M. Chan

#### BMSC approved Trials in Development

A071701: Molecularly-driven trial in brain metastases P. Brastianos  
E. Galanis

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease P. Brown

#### New Concepts

Phase I/II Trial of Five Fraction Stereotactic Radiation Therapy for Large Brain Metastases E. Mellon

#### Recently Completed Trials

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases (Brown et al, Lancet Oncology) P. Brown

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (Brown and al, JAMA) P. Brown

### **Anaplastic Gliomas – Newly Diagnosed**

#### Active Protocols

N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma K. Jaeckle

#### Completed Trials

EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial K. Jaeckle

### **Low Grade Glioma-Newly diagnosed**

N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma K. Jaeckle

BN005: A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas A. Mahajan

### **Symptom Control**

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial C. Chung

### **Meningioma**

A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations P. Brastianos  
E. Galanis

BN003: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma P. Brown

### **Craniopharyngioma**

A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas P. Brastianos  
F. Barker

### **Medulloblastoma**

Prospective Randomized Phase II Trial for newly diagnosed Patients with Medulloblastoma or Pineoblastoma A. Mahajan  
H. Shih

### **Other topics**

Targeting Rare Adult CNS Cancers: The NCI-CONNECT Cancer Moonshot Program M. Gilbert  
T. Armstrong

Potential Future Collaborations with the Physical Sciences of Oncology Network J. Sarkaria

Potential rapid assay for MGMT, IDH, G-CIMP, 1p/19q, EGFR, TERT Promotor, ATRX mutation analysis E. Sulman

CANVAS (AFT-28) Trial D. Schrag